{
  "id": "6250787be764a5320400000e",
  "type": "factoid",
  "question": "What is the drug Aduhelm approved for?",
  "ideal_answer": "he Food and Drug Administration (FDA) granted approval for Aduhelm (aducanumab) for the treatment of Alzheimer's disease under its accelerated approval program",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/34657891",
    "http://www.ncbi.nlm.nih.gov/pubmed/34324167",
    "http://www.ncbi.nlm.nih.gov/pubmed/34585212",
    "http://www.ncbi.nlm.nih.gov/pubmed/34554982",
    "http://www.ncbi.nlm.nih.gov/pubmed/34217830"
  ],
  "snippets": [
    {
      "text": "According to the FDA, aducanumab (Aduhelm), the recently approved anti-Alzheimer drug, reduces the level of cerebral amyloid plaques-a hallmark finding in patients with Alzheimer's disease-and this will result in a reduction in clinical decline",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34657891",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Aducanumab (aducanumab-avwa; Aduhelm\u2122) is a human, immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid \u03b2. It has been co-developed by Biogen and Eisai under license from Neurimmune for the treatment of Alzheimer's disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34324167",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Aducanumab (Aduhelm), the first new drug to treat Alzheimer's",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34554982",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "On June 7th 2021, the Food and Drug Administration (FDA) granted approval for Aduhelm (aducanumab) for the treatment of Alzheimer's disease under its accelerated approval program",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34217830",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Aducanumab has been approved by the US Food and Drug Administration for treatment of Alzheimer's disease (AD). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34585212",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "treatment of Alzheimer's disease"
}